REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights

ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m.

PRNewsWire • 14 hours ago

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?

Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 10 hours ago

REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy

REGENXBIO NASDAQ: RGNX outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or wet AMD, during a company event featuring retina specialists and executives.

MarketBeat • Oct 21, 2026

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript

Seeking Alpha • Oct 21, 2026

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m.

PRNewsWire • Oct 12, 2026

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course prophylactic topical steroids ROCKVILLE, Md., Sept. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.

PRNewsWire • Sep 24, 2026

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15 at 8:30 a.m.

PRNewsWire • Sep 8, 2026

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.

PRNewsWire • Aug 25, 2026

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

Zacks Investment Research • Aug 25, 2026